88 results about "Thyroiditis" patented technology

The present invention relates to the discovery, identification and characterization of nucleic acids that encode a novel protein differentially expressed within the TH2 cell subpopulation (hereinafter referred to as STIF). The invention encompasses STIF nucleotides, host cell expression systems, STIF proteins, fusion proteins, polypeptides and peptides, antibodies to the STIF protein, transgenic animals that express a STIF transgene, or recombinant knock-out animals that do not express the STIF protein, and compounds that modulate STIF gene expression or STIF activity that can be used for diagnosis, drug screening, clinical trial monitoring, and/or used to treat STIF based disorders, such as proliferative disorders and T-lymphocyte-related disorders including, but not limited to, chronic inflammatory diseases and disorders, such as Crohn's disease, reactive arthritis, including Lyme disease, insulin-dependent diabetes, organ-specific autoimmunity, including multiple sclerosis, Hashimoto's thyroiditis and Grave's disease, contact dermatitis, psoriasis, graft rejection, graft versus host disease, sarcoidosis, atopic conditions, such as asthma and allergy, including allergic rhinitis, gastrointestinal allergies, including food allergies, eosinophilia, conjunctivitis, glomerular nephritis, certain pathogen susceptibilities such as helminthic (e.g., leishmaniasis) and certain viral infections, including HIV, and bacterial infections, including tuberculosis and lepromatous leprosy.

The present invention provides a method of treating or preventing a disease or condition in a patient comprising intravenously administering a therapeutically effective amount of mesenchymal stem cells to the patient, wherein the disease or condition is osteoarthritis, rheumatoid arthritis, multiple sclerosis, stroke, ulcerative colitis, psoriasis, Hashimoto's thyroiditis, atopic dermatitis, allergic rhinitis, chronic obstructive pulmonary disease with bronchial asthma or hearing loss.

A method for the treatment or prevention of autoimmune diseases, allergic or atopic disorders, and graft rejection is provided, comprising inducing the death by apoptosis of a subpopulation of T lymphocytes that is capable of causing such diseases, while leaving substantially unaffected the majority of other T lymphocytes. Cell death is achieved by cycle(s) comprising challenging via immunization these T cells with antigenic substance at short time intervals, or by immunization followed by administering interleukin-2 (IL-2) when these T cells are expressing high levels of IL-2 receptor so as to cause these T cells to undergo apoptosis upon re-immunization with the antigenic peptide or protein. These methods are applicable to the treatment of autoimmune diseases such as, for example, multiple sclerosis, uveitis, arthritis, Type I insulin-dependent diabetes, Hashimoto's thyroiditis, Grave's thyroiditis, autoimmune myocarditis, etc., allergic disorders such as hay fever, extrinsic asthma, or insect bite and sting allergies, food and drug allergies, as well as for the treatment or prevention of graft rejection.

The invention includes processes mainly for the treatment of a inflammatory diseases, such as inflammatory bowel disease, arthritis, atherosclerosis, asthma, allergy, inflammatory kidney disease, circulatory shock, multiple sclerosis, chronic obstructive pulmonary disease, skin inflammation, periodontal disease, psoriasis and T cell-mediated diseases of immunity, including allergic encephalomyelitis, allergic neuritis, transplant allograft rejection, graft versus host disease, myocarditis, thyroiditis, nephritis, systemic lupus erthematosus, and insulin-dependent diabetes mellitus. The processes involve treating a patient with a pharmaceutical composition containing an active ingredient that inhibits the activity of sphingosine kinase.

The present invention relates to furanopyrimidine compounds having the general Formula I:

and stereoisomers, tautomers, solvates, pharmaceutically acceptable salts and derivatives, and prodrugs thereof. The invention also includes pharmaceutical compositions comprising a compound of Formula I, methods of treating various diseases and conditions in a mammal, including inflammation, inhibition of T cell activation, proliferation, arthritis, organ transplant, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease, Crohn's disease, lupus, hypersensitivity, type 1 diabetes, psoriasis, dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Addison's disease, autoimmune diseases, glomerulonephritis, allergic diseases, asthma, hayfever, eczema, cancer, colon carcinoma and thymoma, comprising administering to the mammal a therapeutically effective amount of a compound of Formula I. The invention also relates to methods of manufacturing medicaments, which comprise one or more compounds of Formula I.

The present invention relates to a pharmaceutical composition for preventing or treating thyroid diseases and a food composition for improving thyroid function, comprising an extract from Lonicera caerulea L. car. Edulis fruits as an active ingredient.

The composition of the present invention may be useful for preventing or treating thyroid diseases such as hypothyroidism, hyperthyroidism, thyroid nodule, or thyroditis, and improving thyroid function. Since the extract from Lonicera caerulea L. car. Edulis fruits, which is an active ingredient of the present invention, is derived from natural products, there is no concern for side effects such as toxicity compared to synthetic medicine.

The invention relates to a medication for treating thyroiditis, which is prepared by taking Chinese herbs as raw materials. The medication is prepared from southernwood, wizened scutellariae, cortex moutan, weeping forsythia, isatis root, ptunella vulgaris, picria fel-terrae, balloonflower root and zhebeinine and can be prepared into various common clinical medicine preparations. Proved by clinical test results, the medication has the advantages of definite effect, no toxic and side effect and safe and reliable clinical application.

Hashimoto's Thyroiditis (HT) is the most common type of inflammation of the thyroid gland and accurate diagnosis of HT would be advantageous in predicting thyroid failure. The application presents a three tier architecture for image-based diagnosis and a monitoring application using a network cloud. The presentation layer is run on the tablet (e.g., a mobile device), while the business and persistence layers run on a single network cloud or distributed on different network clouds in a multi-tenancy and multi-user application. Such three tier architecture is used for automated data mining application for diagnosis of Hashimoto's Thyroiditis (HT) Disease using ultrasound.

The invention discloses a traditional Chinese medicine for treating thyroiditis and a preparing method thereof. The traditional Chinese medicine is prepared from, by weight, 15-25 parts of honeysuckle, 10-17 parts of solidago, 9-21 parts of blumea riparia, 3-12 parts of radix cynanchi bungei, 5-11 parts of resina toxicodendri, 9-14 parts of ricepaper pith, 3-8 parts of Indian adenosma, 5-10 parts of symplocos lancifolia, 10-17 parts of common gendarussa herb, 5-10 parts of caulis clematidis armandii, 3-9 parts of gentian, 2-7 parts of semen euphorbiae pulveratum, 1-8 parts of senecio scandens, 2-8 parts of radix berberidis, 11-16 parts of trichosanthes kirilowii maxim, and 6-19 parts of cape jasmine. According to the traditional Chinese medicine, raw materials are easy to obtain, cost is low, and treatment effect is remarkable; furthermore, purely natural crude drugs are matched, and side effects, dependency and drug resistance are avoided; treatment course is short, and the traditional Chinese medicine becomes effective quickly, has a good treatment effect and can be widely applied to prevention, control and treatment of thyroiditis.

The invention discloses a traditional Chinese medicine composition for treating Hashimoto's thyroiditis as well as a preparation method and application of the traditional Chinese medicine composition.The traditional Chinese medicine composition is prepared from the following components in parts by weight: 6 to 15 parts of radix bupleuri, 6 to 20 parts of rhizoma cyperi, 6 to 30 parts of radix scutellariae, 10 to 20 parts of herba epimedii, 10 to 30 parts of radix curcumae, 10 to 30 parts of rhizoma bolbostemmae, 6 to 15 parts of airpotato yam rhizome, 6 to 15 parts of rhizoma curcumae, 10 to30 parts of shells of fructus trichosanthis, 6 to 15 parts of semen citri reticulatae, 6 to 15 parts of ginger processed rhizoma pinelliae, 6 to 15 parts of rumex japonicus, 6 to 15 parts of fiveleafakebia fruit, 3 to 9 parts of spanishneedles herb, 6 to 30 parts of roasted malt, 6 to 12 parts of galium aparine, 6 to 15 parts of rhizoma campylandra chinensis, and 10 to 30 parts of herba oldenlandiae diffusae. All herbs are combined to produce a synergistic effect and to play an efficacy for promoting the circulation of qi, reducing the phlegm, invigorating the circulation of blood, removing the stasis, clearing away the internal heat, eliminating the toxicity, warming Yang, and invigorating the spleen. The traditional Chinese medicine composition has the advantages of accurate formula, definite curative effect, simplicity, good effect and the like. The clinical observation shows that the traditional Chinese medicine composition has the effect for reducing thyroid associated antibodies, adjusting the thyroid function and improving the thyroid nodule and is suitable for the clinical popularization and application.

Pharmaceutical compositions are provided that are useful in treating immunological diseases. The compositions comprise a pharmaceutically acceptable carrier, and an effective therapeutic or prophylactic amount of a nitroxide antioxidant that alters the expression of a gene related to an immunological disease. Methods are also provided for the use of the pharmaceutical compositions in the treatment or prevention of immunological disease. In a preferred embodiment, the nitroxide antioxidant is Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl); the gene is one of glucocorticoid-induced leucine zipper, collagen type I alpha 1, and complement component 6; and the immunological disease is Graves' disease, Hashimoto's thyroiditis, autoimmune polyglandular syndrome, insulin-dependent diabetes mellitus, insulin-independent diabetes mellitus, immune-mediated infertility, autoimmune Addison's disease, pemphigus vulgaris, pemphigus foliaceus, dermatitis herpetiformus, vitiligo, autoimmune hemolytic anemia, autoimmune thrombocytopenic purpura, pernicious anemia, myasthenia gravis, multiple sclerosis, Guillain-Barre syndrome, stiff-man syndrome, acute rheumatic fever, sympathetic ophthalmia, Goodpasture's syndrome, systemic lupus erythematosus, rheumatoid arthritis, systemic necrotizing vasculitis, Wegener's granulomatosis, antiphospholipid syndrome, Sjögren's syndrome, scleroderma, accelerated graft arteriosclerosis, graft-versus-host disease, Crohn's disease, or tuberculosis.

The invention relates to a medicine for treating deficiency syndrome, its preparing process and usage, wherein the medicine is prepared from fleece-flower root, root of red rooted saliva, Ligusticum wallichii, wolferry fruit, pipe-fish, long-nosed pit viper through the conventional process.

The invention relates to a medicament for injection, in particular to an injection medicament for treating chronic lymphoid thyreoitis. The medicament is prepared by mixing methylprednisolone sodium succinate for injection, cyclophosphamide for injection and 2 percent lignocaine injection in certain mixing ratio. The medicament is injected locally, and medicinal strength cannot involve the whole body, which is favorable for deferring and protecting other parts of the body against medicament erosion and has small hormone irritability.

The Chinese patented medicine for treating cholecystitis is prepared with fresh pig bile. The preparation process includes following steps: heating fresh pig bile inside enamel container in slow fire to become ropy while stirring to eliminate bubbles; cooling the container in water at 5-15 deg.c to solidify the ropy pig bile into solid; grinding solidified pig bile into powder and 200-mesh sieving; and capsulizing the pig bile powder in 0.32-0.38 g each. The Chinese patented medicine is used for treating cholecystitis, pancreatitis, thyroiditis, mastitis and toothache effectively and has no side effect and bad reaction.

The invention discloses a traditional Chinese medicine cataplasma for treating autoimmune thyroiditis, and a preparation method of the traditional Chinese medicine cataplasma. The effective components of the traditional Chinese medicine cataplasma are prepared from the following raw materials in parts by weight: 45-55 parts of thunberg fritillary bulb, 15-25 parts of Chinese yam, 5-10 parts of radix isatidis, 8-15 parts of albizia flower and 5-10 parts of acaudina molpadioides. The invention further discloses a preparation method of the traditional Chinese medicine cataplasma. An experiment result proves that the traditional Chinese medicine cataplasma disclosed by the invention has a good treatment effect on the autoimmune thyroiditis, is good in transdermal absorption effect, has the advantages of rapidly releasing medicines and rapidly playing medicine effects, and has good clinical application value; and metabolism of the medicine in gastrointestinal tracts can be avoided.

The invention discloses application of airpotato yam rhizome in preparation of medicaments for treating thyroid. The airpotato yam rhizome is prepared into an external preparation which has a remarkable curative effect of treating thyroid disease, is high in cure rate and almost does not have side effect in external application. When airpotato yam rhizome tincture is used, only the medicinal liquid of the tincture is externally applied to coating, smearing or spraying at the affected part, diseases on the aspect of the thyroid such as thyroid nodule, thyroid cyst, thyroid enlargement, thyroiditis and thyroid tumors can be healed, the medicament is not required to be orally taken or externally applied, and troubles of decoction and external application are avoided; and the raw medicinal materials are wide in source and low in cost, obvious toxic or side effect on external application is avoided, burden of a patient is effectively lightened, and negative effects on high operation cost, scar leaving, relapse and the like are avoided.

The invention discloses a medicine for treating thyroiditis and a preparation method, which belong to the field of traditional Chinese medicines. The raw materials of the effective ingredients of the medicine disclosed by the invention are gomphostemma root, incised spleenwort, radix puerariae, mahonia bealei carr, medlar, aristolochia kaempferi, cyrtomium fortunei, pogostemon cablin, japanese polygala, mirabilite, clerodendron cyrtophyllum root, scaposum var. vaginatum, honewort, agaric, ficus pyriformis and ceiba root. The medicine disclosed by the invention is suitable in the compatibility of the selected medicinal materials, meets the theories of traditional Chinese medicine and modern medicine and pharmacology, has the effects of soothing liver-qi stagnation, eliminating sputum and softening hard mass, tonifying spleen and kidney, and promoting qi to activate blood, has a remarkable curative effect on thyroiditis, is short in treatment course, fast becomes effective, and is free from reappearance after cure, safe and reliable, free from any toxic and side effect, low in price, capable of treating both symptoms and root causes, and worthy of wide popularization and application in clinical.